JAK2 shRNA Plasmid (h) from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

JAK2 shRNA Plasmid (h)

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
JAK2 shRNA Plasmid (h)

Product Specs
ItemJAK2 shRNA Plasmid (h)
CompanySanta Cruz Biotechnology, Inc.
Price $592.00Supplier Page View Company Product Page
Catalog Numbersc-39099-SH
Quantity20 µg
RNA TypeshRNA Clones
Vector Type (Standardized)Lentiviral
TypeshRNA Plasmid
Specieshuman
NCBI Full Gene NameJanus kinase 2
NCBI Gene AliasesJTK10

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) STAT3 ameliorates cognitive deficits by positively regulating the expression of NMDARs in a mouse model of FTDP-17Signal transduction and targeted therapyDecember 26, 2020Hong XY, Wan HL, Li T, Zhang BG, Li XG, Wang X, Li X, Liu Q, Chen CY, Yang Y, et al.

(2) Interleukin4Rα (IL4Rα) and IL13Rα1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) PathwaysCancersSeptember 18, 2019Kang MA, Lee J, Ha SH, Lee CM, Kim KM, Jang KY, Park SH.

(3) Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemiaJournal of cellular physiologyAugust 1, 2019Wang HQ, Jia L, Li YT, Farren T, Agrawal SG, Liu FT.

(4) Tau accumulation triggers STAT1-dependent memory deficits by suppressing NMDA receptor expressionEMBO reportsJune 1, 2019Li XG, Hong XY, Wang YL, Zhang SJ, Zhang JF, Li XC, Liu YC, Sun DS, Feng Q, Ye JW, et al.

(5) A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathwayOncotargetOctober 13, 2015Zhao H, Guo Y, Li S, Han R, Ying J, Zhu H, Wang Y, Yin L, Han Y, Sun L, et al.

(6) Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cellsJournal of hematology & oncologyApril 28, 2014Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K.

(7) Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivoMolecular medicine reportsMay 1, 2013Zhang LL, Zhang J, Shen L, Xu XM, Yu HG.

(8) Regulation of AKT gene expression by cisplatinOncology lettersMarch 1, 2013Zhang J, Zhang LL, Shen L, Xu XM, Yu HG.

(9) TGF-beta1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cellsCellular signallingNovember 1, 2010Starsíchová A, Lincová E, Pernicová Z, Kozubík A, Soucek K.

(10) Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplificationCancer researchApril 15, 2010Dudka AA, Sweet SM, Heath JK.

(11) Procaspase 8 and Bax are up-regulated by distinct pathways in Streptococcal pyrogenic exotoxin B-induced apoptosisThe Journal of biological chemistryNovember 27, 2009Chang CW, Tsai WH, Chuang WJ, Lin YS, Wu JJ, Liu CC, Tsai PJ, Lin MT.

(12) p52Shc is required for CXCR4-dependent signaling and chemotaxis in T cellsBloodSeptember 15, 2007Patrussi L, Ulivieri C, Lucherini OM, Paccani SR, Gamberucci A, Lanfrancone L, Pelicci PG, Baldari CT.

Be the First to Write a Review!